Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalequal togreaterpatients mustheart
  Phrases that lowered it: blood pressureparticipantcombinationsarcomaantiretroviral
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.5% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 210 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 308 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Maximum age: 16 (raises risk) · Who can join
• Drug's FAERS reports with a death: 0% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Sunitinib or Cediranib for Alveolar Soft Part Sarcoma NCT01391962 · started 2011 · scored riskier than 20% of active trials completed
• AZD7451 for Recurrent Gliomas NCT01468324 · started 2011 · scored riskier than 68% of active trials completed
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer NCT00937482 · started 2009 · scored riskier than 85% of active trials terminated
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 · started 2014 · scored riskier than 76% of active trials completed
• Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery NCT01206140 · started 2010 · scored riskier than 72% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.